Navigation Links
Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
Date:8/25/2011

nths and is used as a marker to determine the efficacy of glucose-lowering therapies.

"Linagliptin is primarily excreted unmetabolized via bile and gut, meaning no dose adjustment is needed in adult patients with kidney or liver impairment," said Prof. Anthony Barnett, professor of medicine and clinical director of the Department of Diabetes and Endocrinology, Heart of England NHS Foundation Trust, Birmingham, UK. "This means that linagliptin is available at only one dose."

The approval of linagliptin in Europe was based on a clinical trial program which involved approximately 6,000 adults with type 2 diabetes. Included in the program were placebo-controlled studies evaluating linagliptin as monotherapy(4) and in combination with the commonly prescribed oral antihyperglycemic medications metformin and/or sulfonylurea.(2,5-6) In two monotherapy studies, linagliptin showed a statistically significant mean difference in A1C from placebo of -0.6 to -0.7 percent.(3-4) In patients who were not adequately controlled on metformin or metformin plus sulfonylurea, the addition of linagliptin also resulted in a statistically significant mean difference in A1C from placebo of -0.6 percent.(2,5) The incidence of hypoglycemia was similar to placebo and weight did not change significantly from baseline.(2,5)

In the pooled analysis of the placebo-controlled trials, the overall incidence of adverse events in patients treated with placebo was similar to that seen with linagliptin (53.8 percent versus 55.0 percent).

The most frequently reported adverse reaction was hypoglycemia observed with the triple combination of linagliptin plus metformin plus sulfonylurea.

"The EU approval of linagliptin marks another major regulatory milestone for the Boehringer Ingelheim and Lilly alliance in diabetes," said Enrique Conterno, president of Lilly Diabetes. "Linagliptin can be an important treatment option for adults living with type 2 diabetes."

Wha
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
2. FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
3. Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. CryoCor Receives FDA Approval for Right Atrial Flutter
10. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
11. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...   Hospira, Inc. (NYSE: HSP ... infusion technologies, today announced that the company will present ... Wednesday, Jan. 14, 2015, in San Francisco.  ... 10:30 a.m. Pacific time on Wednesday, Jan. 14, 2015.  ... a live audiocast accessible via the Investor Relations section ...
(Date:12/19/2014)... HILL, N.C. , Dec. 19, 2014 /PRNewswire/ ... innovative consumer research and marketing communication tools are ... and globally competitive – consequently consumers, desires, preferences, ... In this environment, market research groups across all ... and marketing communication tools. However, the adoption of ...
(Date:12/19/2014)... SAN DIEGO and CARDIFF-BY-THE-SEA, ... Therapeutics, Inc. (NASDAQ: SRNE ;  Sorrento), ... and associated pain, and Conkwest, Inc., a privately-held ... a Natural Killer (NK) cell-line based therapy, announced ... definitive agreement to jointly develop next generation CAR-TNK™ ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5
... BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- ... the development of,novel, proprietary antibody-based products for ... study published recently,in the Proceedings of the ... of several other studies that EpCAM (CD326), ...
... LOS ANGELES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx ... and commercialization of human therapeutics, today,announced promising ... completed Phase IIa clinical trial with arimoclomol ... not placebo-controlled,arimoclomol at a 100 mg dose ...
Cached Medicine Technology:Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers 2Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers 3Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers 4CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 2CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 3CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 4CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 5
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- The intestinal bacteria that ... ulcerative colitis, may be inherited, researchers report. The ... , could help in efforts to prevent the disease ... colitis, the study authors added. "The intestinal bacteria, ... age can have a big impact on your health ...
(Date:12/19/2014)... -- Potentially illness-causing E. coli bacteria were found on ... to a new study. Researchers checked cilantro, basil ... markets in Los Angeles and Orange counties in California, ... samples tested, 24 percent were positive for E. coli. ... researchers. Both types of bacteria can cause sometimes ...
(Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- Dense bunches of bacteria ... cancers, a new study finds. The researchers said ... the colon. The presence of these biofilms may represent ... new way to predict a person,s risk for the disease, ... pond stones, these biofilms may coat the mucus layer of ...
(Date:12/19/2014)... News) -- Older adults who have lost all their teeth ... who still have at least some of their teeth, a ... loss could provide an early warning of increased risk of ... said. However, the findings don,t prove that tooth loss ... more than 3,100 participants 60 and older. People with no ...
(Date:12/19/2014)... December 19, 2014 Diet Doc strives ... current approach to weight loss by combining ... The professionals at the company understand that remaining committed ... effects of eliminating carbohydrates and sugars from the diet ... to abandon their weight loss goals. , For ...
Breaking Medicine News(10 mins):Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Could Bacteria Play a Role in Colon Cancer? 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4
... Conference on Cell Therapy for Cardiovascular Disease sponsored ... comprehensive program dedicated to the evolving field of ... cardiac and vascular disease, as well as related ... conference will focus on preclinical and clinical studies ...
... The March of Dimes, along with its partners, are giving ... to learn from each other and to work together to ... give more babies a healthy start. U.S. Surgeon ... Prevention Symposium. The symposium will was a forum to share ...
... of researchers has discovered 13 new regions of the genome ... on the biological pathways involved in reproductive lifespan and will ... cancer and heart disease. Menopause is a ... in their early 50s. The timing of menopause can have ...
... Kathleen Doheny HealthDay Reporter , SUNDAY, Jan. ... genomic regions they believe are linked with breast cancer ... disease. All three newly identified areas "contain interesting ... clinical research," said researcher Douglas Easton, a professor of ...
... 2012) Research to Prevent Blindness (RPB) has awarded ... School, a $30,000 Medical Student Eye Research Fellowship. The award ... award will allow Ms. Shah to participate in research under ... Dr. Louis Pasquale in collaboration with Dr. Suzanne Freitag, Director ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, Jan. ... moratorium on controversial research into a modified avian flu virus ... Although the investigators believe their research has a public ... others that the genetically altered virus could escape from labs ...
Cached Medicine News:Health News:Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC 2Health News:Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC 3Health News:March of Dimes launches Prematurity Prevention Network 2Health News:March of Dimes launches Prematurity Prevention Network 3Health News:Genes and timing of menopause 2Health News:New Genetic Clues to Breast Cancer? 2Health News:New Genetic Clues to Breast Cancer? 3Health News:Scientists Agree to Delay Controversial Bird Flu Research 2Health News:Scientists Agree to Delay Controversial Bird Flu Research 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: